Loading…
Loading…
CVSI does not currently pay a dividend.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for CVSI and 80,000+ other tickers.
See exactly how CVSI's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for CVSI and 80,000+ other tickers.
CV Sciences, Inc. functions as a life sciences organization primarily operating across North America. Its business activities are organized into two distinct divisions: Consumer Products and Specialty Pharmaceutical. The Consumer Products division focuses on the creation, manufacturing, and commercialization of plant-derived dietary supplements and cannabidiol (CBD) products sourced from hemp. These offerings are marketed under various brand identities including PlusCBD, ProCBD, HappyLane, CV Acute, CV Defense, and PlusCBD Pet. They serve a wide array of health and wellness sectors such as…
CV Sciences, Inc. (CVSI) Q2 2026 Earnings Call Transcript
SAN DIEGO, CA / ACCESS Newswire / August 13, 2026 / CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extracts and other proven science-backed, natural ingredients and products, today announced its financial results for the quarter ended June 30, 2026. Second Quarter 2026 and Recent Financial, Operating and Regulatory Highlights Generated revenue of $3.0 million for the second quarter 2026 compared to $3.6 million for the second quarter 2025 and compared to $3.2 million for the first quarter 2026; Recognized gross margin of 48.6% for the second quarter 2026 compared to 50.9% for the second quarter 2025 and compared to 48.9% for the first quarter 2026; Cash balance of $0.3 million at quarter and year end; Reduced operating expenses by 11.3% to $1.7 million for the second quarter 2026 compared to $2.0 million for the second quarter 2025, and by 6.9% from $1.9 million in the first quarter 2026; Recognized an adjusted EBITDA loss of $0.1 million for the second quarter 2026 compared to positive adjusted EBITDA of $0.1 million for second quarter 2025 and compared to an adjusted EBITDA loss of $0.1 million for the first quarter 2026; Expanded the +PlusHLTH™ portfolio with personalized wellness solutions for healthy aging; Launched PlusHLTH.com, a new dedicated e-commerce platform strengthens the Company's strategy to build a leading science-backed health and wellness portfolio; and U.S. Senate voted 61-32 to approve Continuing Resolution H.R.
New digital destination brings the Company's Health Intelligence approach to life, helping consumers better understand their needs, discover science-backed solutions, and navigate healthy aging. SAN DIEGO, CA / ACCESS Newswire / August 11, 2026 / CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "our", "us" or "we"), a consumer health company specializing in science-backed natural ingredients and products, today announced the launch of PlusHLTH.com, a new direct-to-consumer destination dedicated exclusively to the Company's growing +PlusHLTH™ product line.
SAN DIEGO, CA / ACCESS Newswire / August 10, 2026 / CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extracts and other proven, science-backed natural ingredients and products, today announced that it will release financial results for the second quarter ended June 30, 2026, after the stock market closes on Thursday, August 13, 2026. The Company will hold a conference call with the investment community at 1:30 p.m.
Built on the Company's Health Intelligence™ Approach, the New Products Help Consumers Create Personalized Wellness Routines That Support Overall Health and Long-Term Vitality SAN DIEGO, CA / ACCESS Newswire / June 25, 2026 / CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a consumer wellness company specializing in science-backed natural ingredients and products, today announced the expansion of its +PlusHLTH™ supplement portfolio with additional formulations supporting cellular integrity, metabolism, cognitive health, cardiovascular wellness, and movement. Health Intelligence is CV Sciences' approach to personalized wellness, combining thoughtful formulations that support key areas of health targeting multiple pathways to support metabolism, brain health, cardiovascular wellness, movement, stress resilience, and vitality.